{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:21:50Z","timestamp":1793730110600,"version":"4.6.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite aggressive therapeutic regimens, glioblastoma (GBM) represents a deadly brain tumor with significant aggressiveness, radioresistance and chemoresistance, leading to dismal prognosis. Hypoxic microenvironment, which characterizes GBM, is associated with reduced therapeutic effectiveness. Moreover, current irradiation approaches are limited by uncertain tumor delineation and severe side effects that comprehensively lead to unsuccessful treatment and to a worsening of the quality of life of GBM patients. Proton beam offers the opportunity of reduced side effects and a depth-dose profile, which, unfortunately, are coupled with low relative biological effectiveness (RBE). The use of radiosensitizing agents, such as boron-containing molecules, enhances proton RBE and increases the effectiveness on proton beam-hit targets. We report a first preclinical evaluation of proton boron capture therapy (PBCT) in a preclinical model of GBM analyzed via \u03bc-positron emission tomography\/computed tomography (\u03bcPET-CT) assisted live imaging, finding a significant increased therapeutic effectiveness of PBCT versus proton coupled with an increased cell death and mitophagy. Our work supports PBCT and radiosensitizing agents as a scalable strategy to treat GBM exploiting ballistic advances of proton beam and increasing therapeutic effectiveness and quality of life in GBM patients.<\/jats:p>","DOI":"10.1038\/s42003-023-04770-w","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T15:02:34Z","timestamp":1680966154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Proton boron capture therapy (PBCT) induces cell death and mitophagy in a heterotopic glioblastoma model"],"prefix":"10.1038","volume":"6","author":[{"given":"Francesco Paolo","family":"Cammarata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Torrisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5934-3962","authenticated-orcid":false,"given":"Nunzio","family":"Vicario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bravat\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Salvatorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"D\u2019Aprile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangela","family":"Giustetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusi Irma","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3112-4519","authenticated-orcid":false,"given":"Luigi","family":"Minafra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Calvaruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selene","family":"Richiusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5733-9281","authenticated-orcid":false,"given":"Giuseppe Antonio Pablo","family":"Cirrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Petringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2576-6523","authenticated-orcid":false,"given":"Giuseppe","family":"Broggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Scopelliti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Porro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Libra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1493-1087","authenticated-orcid":false,"given":"Giorgio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1614-4696","authenticated-orcid":false,"given":"Rosalba","family":"Parenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Cuttone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,8]]},"reference":[{"key":"4770_CR1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cmpb.2017.03.011","volume":"144","author":"L Rundo","year":"2017","unstructured":"Rundo, L. et al. A fully automatic approach for multimodal PET and MR image segmentation in gamma knife treatment planning. Comput Methods Prog. Biomed. 144, 77\u201396 (2017).","journal-title":"Comput Methods Prog. Biomed."},{"key":"4770_CR2","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.21873\/anticanres.12954","volume":"38","author":"C Scaringi","year":"2018","unstructured":"Scaringi, C., Agolli, L. & Minniti, G. Technical Advances in Radiation Therapy for Brain Tumors. Anticancer Res. 38, 6041\u20136045 (2018).","journal-title":"Anticancer Res."},{"key":"4770_CR3","unstructured":"Tamimi, A. F. & Juweid, M. In Glioblastoma (ed S. De Vleeschouwer) (2017)."},{"key":"4770_CR4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1215\/15228517-2006-025","volume":"9","author":"KV Ballman","year":"2007","unstructured":"Ballman, K. V. et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 9, 29\u201338 (2007).","journal-title":"Neuro Oncol."},{"key":"4770_CR5","doi-asserted-by":"publisher","unstructured":"Bravata, V. et al. Hypoxia Transcriptomic Modifications Induced by Proton Irradiation in U87 Glioblastoma Multiforme Cell Line. J Pers Med. 11, https:\/\/doi.org\/10.3390\/jpm11040308 (2021).","DOI":"10.3390\/jpm11040308"},{"key":"4770_CR6","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3390\/biomedicines10040806","volume":"10","author":"F Torrisi","year":"2022","unstructured":"Torrisi, F. et al. The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression. Biomedicines 10, 806 (2022).","journal-title":"Biomedicines"},{"key":"4770_CR7","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.3390\/cancers12102860","volume":"12","author":"F Torrisi","year":"2020","unstructured":"Torrisi, F. et al. The Role of Hypoxia and SRC Tyrosine Kinase in Glioblastoma Invasiveness and Radioresistance. Cancers 12, 2860 (2020).","journal-title":"Cancers"},{"key":"4770_CR8","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3389\/fneur.2017.00748","volume":"8","author":"J Mann","year":"2017","unstructured":"Mann, J., Ramakrishna, R., Magge, R. & Wernicke, A. G. Advances in Radiotherapy for Glioblastoma. Front Neurol. 8, 748 (2017).","journal-title":"Front Neurol."},{"key":"4770_CR9","doi-asserted-by":"crossref","first-page":"20130626","DOI":"10.1259\/bjr.20130626","volume":"87","author":"M Durante","year":"2014","unstructured":"Durante, M. New challenges in high-energy particle radiobiology. Br. J. Radio. 87, 20130626 (2014).","journal-title":"Br. J. Radio."},{"key":"4770_CR10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fonc.2017.00301","volume":"7","author":"M Durante","year":"2017","unstructured":"Durante, M., Cucinotta, F. A. & Loeffler, J. S. Editorial: Charged Particles in Oncology. Front Oncol. 7, 301 (2017).","journal-title":"Front Oncol."},{"key":"4770_CR11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3390\/cancers7010353","volume":"7","author":"F Tommasino","year":"2015","unstructured":"Tommasino, F. & Durante, M. Proton radiobiology. Cancers (Basel) 7, 353\u2013381 (2015).","journal-title":"Cancers (Basel)"},{"key":"4770_CR12","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s00066-016-1007-7","volume":"192","author":"S Adeberg","year":"2016","unstructured":"Adeberg, S. et al. Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma: A dosimetric comparison. Strahlenther. Onkol. 192, 770\u2013779 (2016).","journal-title":"Strahlenther. Onkol."},{"key":"4770_CR13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2018.05.001","volume":"128","author":"M Lambrecht","year":"2018","unstructured":"Lambrecht, M. et al. Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. Radiother. Oncol. 128, 26\u201336 (2018).","journal-title":"Radiother. Oncol."},{"key":"4770_CR14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41416-018-0329-x","volume":"120","author":"M Durante","year":"2019","unstructured":"Durante, M. Proton beam therapy in Europe: more centres need more research. Br. J. Cancer. 120, 777\u2013778 (2019).","journal-title":"Br. J. Cancer."},{"key":"4770_CR15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.semradonc.2012.11.002","volume":"23","author":"H Paganetti","year":"2013","unstructured":"Paganetti, H. & van Luijk, P. Biological considerations when comparing proton therapy with photon therapy. Semin Radiat. Oncol. 23, 77\u201387 (2013).","journal-title":"Semin Radiat. Oncol."},{"key":"4770_CR16","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00432-020-03187-w","volume":"146","author":"D Scartoni","year":"2020","unstructured":"Scartoni, D., Amelio, D., Palumbo, P., Giacomelli, I. & Amichetti, M. Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma. J. Cancer Res Clin. Oncol. 146, 1615\u20131622 (2020).","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"4770_CR17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.clineuro.2018.08.003","volume":"174","author":"E Thurin","year":"2018","unstructured":"Thurin, E. et al. Proton therapy for low-grade gliomas in adults: A systematic review. Clin. Neurol. Neurosurg. 174, 233\u2013238 (2018).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"4770_CR18","volume":"8","author":"GAP Cirrone","year":"2018","unstructured":"Cirrone, G. A. P. et al. First experimental proof of Proton Boron Capture Therapy (PBCT) to enhance protontherapy effectiveness. Sci. Rep. 8, 1141 (2018).","journal-title":"Sci. Rep."},{"key":"4770_CR19","doi-asserted-by":"crossref","first-page":"682647","DOI":"10.3389\/fonc.2021.682647","volume":"11","author":"P Blaha","year":"2021","unstructured":"Blaha, P. et al. The Proton-Boron Reaction Increases the Radiobiological Effectiveness of Clinical Low- and High-Energy Proton Beams: Novel Experimental Evidence and Perspectives. Front Oncol. 11, 682647 (2021).","journal-title":"Front Oncol."},{"key":"4770_CR20","doi-asserted-by":"crossref","first-page":"39774","DOI":"10.18632\/oncotarget.15700","volume":"8","author":"JY Jung","year":"2017","unstructured":"Jung, J. Y. et al. Comparison between proton boron fusion therapy (PBFT) and boron neutron capture therapy (BNCT): a monte carlo study. Oncotarget 8, 39774\u201339781 (2017).","journal-title":"Oncotarget"},{"key":"4770_CR21","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen, P. Y. et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 22, 1073\u20131113 (2020).","journal-title":"Neuro Oncol."},{"key":"4770_CR22","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.3390\/ijms20215267","volume":"20","author":"M Calvaruso","year":"2019","unstructured":"Calvaruso, M. et al. Nutraceutical Compounds as Sensitizers for Cancer Treatment in Radiation Therapy. Int J. Mol. Sci. 20, 5267 (2019).","journal-title":"Int J. Mol. Sci."},{"key":"4770_CR23","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/j.seminoncol.2014.09.013","volume":"41","author":"DE Citrin","year":"2014","unstructured":"Citrin, D. E. & Mitchell, J. B. Altering the response to radiation: sensitizers and protectors. Semin Oncol. 41, 848\u2013859 (2014).","journal-title":"Semin Oncol."},{"key":"4770_CR24","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.3390\/ijms20112723","volume":"20","author":"GA Malfa","year":"2019","unstructured":"Malfa, G. A. et al. Betula etnensis Raf. (Betulaceae) Extract Induced HO-1 Expression and Ferroptosis Cell Death in Human Colon Cancer Cells. Int J. Mol. Sci. 20, 2723 (2019).","journal-title":"Int J. Mol. Sci."},{"key":"4770_CR25","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.3390\/ijms20194745","volume":"20","author":"FP Cammarata","year":"2019","unstructured":"Cammarata, F. P. et al. Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line. Int J. Mol. Sci. 20, 4745 (2019).","journal-title":"Int J. Mol. Sci."},{"key":"4770_CR26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-22022-4","volume":"8","author":"P Lesueur","year":"2018","unstructured":"Lesueur, P. et al. Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation. Sci. Rep. 8, 3664 (2018).","journal-title":"Sci. Rep."},{"key":"4770_CR27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.14338\/IJPT-18-00019.1","volume":"5","author":"K Tsuboi","year":"2018","unstructured":"Tsuboi, K. Advantages and Limitations in the Use of Combination Therapies with Charged Particle Radiation Therapy. Int J. Part Ther. 5, 122\u2013132 (2018).","journal-title":"Int J. Part Ther."},{"key":"4770_CR28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.apradiso.2010.11.018","volume":"69","author":"S Bortolussi","year":"2011","unstructured":"Bortolussi, S. et al. Boron uptake measurements in a rat model for Boron Neutron Capture Therapy of lung tumours. Appl Radiat. Isot. 69, 394\u2013398 (2011).","journal-title":"Appl Radiat. Isot."},{"key":"4770_CR29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-43453-7","volume":"9","author":"K Jasinska-Konior","year":"2019","unstructured":"Jasinska-Konior, K. et al. Increased elasticity of melanoma cells after low-LET proton beam due to actin cytoskeleton rearrangements. Sci. Rep. 9, 7008 (2019).","journal-title":"Sci. Rep."},{"key":"4770_CR30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/09553002.2020.1683637","volume":"96","author":"M Suzuki","year":"2020","unstructured":"Suzuki, M., Yasuda, N. & Kitamura, H. Lethal and mutagenic bystander effects in human fibroblast cell cultures subjected to low-energy-carbon ions. Int J. Radiat. Biol. 96, 179\u2013186 (2020).","journal-title":"Int J. Radiat. Biol."},{"key":"4770_CR31","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1128\/MCB.18.7.4209","volume":"18","author":"F Kiefer","year":"1998","unstructured":"Kiefer, F. et al. The Syk protein tyrosine kinase is essential for Fcgamma receptor signaling in macrophages and neutrophils. Mol. Cell Biol. 18, 4209\u20134220 (1998).","journal-title":"Mol. Cell Biol."},{"key":"4770_CR32","first-page":"2002787","volume":"8","author":"C Gong","year":"2021","unstructured":"Gong, C. et al. Tumor Exosomes Reprogrammed by Low pH Are Efficient Targeting Vehicles for Smart Drug Delivery and Personalized Therapy against their Homologous Tumor. Adv. Sci. (Weinh.) 8, 2002787 (2021).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"4770_CR33","doi-asserted-by":"crossref","first-page":"9845","DOI":"10.3390\/ijms22189845","volume":"22","author":"S Lee","year":"2021","unstructured":"Lee, S. et al. BEX1 and BEX4 Induce GBM Progression through Regulation of Actin Polymerization and Activation of YAP\/TAZ Signaling. Int J. Mol. Sci. 22, 9845 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"4770_CR34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jrr\/rrz032","volume":"60","author":"V Bravata","year":"2019","unstructured":"Bravata, V. et al. Proton-irradiated breast cells: molecular points of view. J. Radiat. Res. 60, 451\u2013465 (2019).","journal-title":"J. Radiat. Res."},{"key":"4770_CR35","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.3390\/cancers13215393","volume":"13","author":"S Guelfi","year":"2021","unstructured":"Guelfi, S. et al. SLUG and Truncated TAL1 Reduce Glioblastoma Stem Cell Growth Downstream of Notch1 and Define Distinct Vascular Subpopulations in Glioblastoma Multiforme. Cancers (Basel) 13, 5393 (2021).","journal-title":"Cancers (Basel)"},{"key":"4770_CR36","first-page":"5933","volume":"11","author":"F Giordano","year":"2021","unstructured":"Giordano, F., Montalto, F. I., Panno, M. L., Ando, S. & De Amicis, F. A Notch inhibitor plus Resveratrol induced blockade of autophagy drives glioblastoma cell death by promoting a switch to apoptosis. Am. J. Cancer Res. 11, 5933\u20135950 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"4770_CR37","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/jcp.27033","volume":"234","author":"H Ma","year":"2019","unstructured":"Ma, H. et al. NKCC1 promotes EMT-like process in GBM via RhoA and Rac1 signaling pathways. J. Cell Physiol. 234, 1630\u20131642 (2019).","journal-title":"J. Cell Physiol."},{"key":"4770_CR38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/neuonc\/nox119","volume":"20","author":"I Olmez","year":"2018","unstructured":"Olmez, I. et al. Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol. 20, 192\u2013202 (2018).","journal-title":"Neuro Oncol."},{"key":"4770_CR39","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/neuonc\/nou228","volume":"17","author":"Y Ma","year":"2015","unstructured":"Ma, Y. et al. Critical functions of RhoB in support of glioblastoma tumorigenesis. Neuro Oncol. 17, 516\u2013525 (2015).","journal-title":"Neuro Oncol."},{"key":"4770_CR40","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1080\/15548627.2019.1618540","volume":"15","author":"A Vehlow","year":"2019","unstructured":"Vehlow, A. & Cordes, N. DDR1 (discoidin domain receptor tyrosine kinase 1) drives glioblastoma therapy resistance by modulating autophagy. Autophagy 15, 1487\u20131488 (2019).","journal-title":"Autophagy"},{"key":"4770_CR41","first-page":"162","volume":"23","author":"LA Wilkerson","year":"1987","unstructured":"Wilkerson, L. A. Defining our cultures\u2013bridging the gap. Birth Defects Orig. Artic. Ser. 23, 162\u2013163 (1987).","journal-title":"Birth Defects Orig. Artic. Ser."},{"key":"4770_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11033-021-06607-3","volume":"48","author":"A Mardanshahi","year":"2021","unstructured":"Mardanshahi, A., Gharibkandi, N. A., Vaseghi, S., Abedi, S. M. & Molavipordanjani, S. The PI3K\/AKT\/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines. Mol. Biol. Rep. 48, 1\u201314 (2021).","journal-title":"Mol. Biol. Rep."},{"key":"4770_CR43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55296-3","volume":"9","author":"R Shiratori","year":"2019","unstructured":"Shiratori, R. et al. Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner. Sci. Rep. 9, 18699 (2019).","journal-title":"Sci. Rep."},{"key":"4770_CR44","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"4770_CR45","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s43018-021-00201-z","volume":"2","author":"M Friedrich","year":"2021","unstructured":"Friedrich, M. et al. Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. Nat. Cancer. 2, 723\u2013740 (2021).","journal-title":"Nat. Cancer."},{"key":"4770_CR46","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1158\/0008-5472.CAN-08-2345","volume":"69","author":"A Detta","year":"2009","unstructured":"Detta, A. & Cruickshank, G. S. L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res. 69, 2126\u20132132 (2009).","journal-title":"Cancer Res."},{"key":"4770_CR47","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/cas.12602","volume":"106","author":"P Wongthai","year":"2015","unstructured":"Wongthai, P. et al. Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. Cancer Sci. 106, 279\u2013286 (2015).","journal-title":"Cancer Sci."},{"key":"4770_CR48","doi-asserted-by":"crossref","DOI":"10.1186\/1748-717X-7-146","volume":"7","author":"RF Barth","year":"2012","unstructured":"Barth, R. F. et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat. Oncol. 7, 146 (2012).","journal-title":"Radiat. Oncol."},{"key":"4770_CR49","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-019-1439-1","volume":"15","author":"M Saager","year":"2020","unstructured":"Saager, M. et al. Fractionated carbon ion irradiations of the rat spinal cord: comparison of the relative biological effectiveness with predictions of the local effect model. Radiat. Oncol. 15, 6 (2020).","journal-title":"Radiat. Oncol."},{"key":"4770_CR50","first-page":"197","volume":"62","author":"N Gupta","year":"2003","unstructured":"Gupta, N., Gahbauer, R. A., Blue, T. E. & Albertson, B. Common challenges and problems in clinical trials of boron neutron capture therapy of brain tumors. J. Neurooncol. 62, 197\u2013210 (2003).","journal-title":"J. Neurooncol."},{"key":"4770_CR51","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S1470-2045(14)70412-7","volume":"16","author":"T Kamada","year":"2015","unstructured":"Kamada, T. et al. Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. Lancet Oncol. 16, e93\u2013e100 (2015).","journal-title":"Lancet Oncol."},{"key":"4770_CR52","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.3390\/ijms21176337","volume":"21","author":"FP Cammarata","year":"2020","unstructured":"Cammarata, F. P. et al. Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams. Int J. Mol. Sci. 21, 6337 (2020).","journal-title":"Int J. Mol. Sci."},{"key":"4770_CR53","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/030089160308900508","volume":"89","author":"C Spatola","year":"2003","unstructured":"Spatola, C. et al. Clinical application of proton beams in the treatment of uveal melanoma: the first therapies carried out in Italy and preliminary results (CATANA Project. Tumori 89, 502\u2013509 (2003).","journal-title":"Tumori"},{"key":"4770_CR54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejmp.2018.07.003","volume":"54","author":"P Pisciotta","year":"2018","unstructured":"Pisciotta, P. et al. Monte Carlo GEANT4-based application for in vivo RBE study using small animals at LNS-INFN preclinical hadrontherapy facility. Phys. Med. 54, 173\u2013178 (2018).","journal-title":"Phys. Med."},{"key":"4770_CR55","doi-asserted-by":"crossref","first-page":"e0233258","DOI":"10.1371\/journal.pone.0233258","volume":"15","author":"P Pisciotta","year":"2020","unstructured":"Pisciotta, P. et al. Evaluation of proton beam radiation-induced skin injury in a murine model using a clinical SOBP. PLoS One. 15, e0233258 (2020).","journal-title":"PLoS One."},{"key":"4770_CR56","doi-asserted-by":"crossref","first-page":"103701","DOI":"10.1016\/j.compbiomed.2020.103701","volume":"120","author":"A Comelli","year":"2020","unstructured":"Comelli, A. et al. Development of a new fully three-dimensional methodology for tumours delineation in functional images. Comput Biol. Med. 120, 103701 (2020).","journal-title":"Comput Biol. Med."},{"key":"4770_CR57","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/jimaging8040092","volume":"8","author":"V Benfante","year":"2022","unstructured":"Benfante, V. et al. A New Preclinical Decision Support System Based on PET Radiomics: A Preliminary Study on the Evaluation of an Innovative (64)Cu-Labeled Chelator in Mouse Models. J. Imaging. 8, 92 (2022).","journal-title":"J. Imaging."},{"key":"4770_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.compbiomed.2018.09.002","volume":"102","author":"A Comelli","year":"2018","unstructured":"Comelli, A. et al. A smart and operator independent system to delineate tumours in Positron Emission Tomography scans. Comput Biol. Med. 102, 1\u201315 (2018).","journal-title":"Comput Biol. Med."},{"key":"4770_CR59","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young, H. et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer. 35, 1773\u20131782 (1999).","journal-title":"Eur. J. Cancer."},{"key":"4770_CR60","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2174\/157340561104150727165035","volume":"11","author":"A Stefano","year":"2015","unstructured":"Stefano, A. et al. Metabolic Response Assessment in Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A Preliminary Analysis. Curr. Med. Imaging Rev. 11, 218\u2013227 (2015).","journal-title":"Curr. Med. Imaging Rev."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04770-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04770-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04770-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T15:05:21Z","timestamp":1680966321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-023-04770-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,8]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4770"],"URL":"https:\/\/doi.org\/10.1038\/s42003-023-04770-w","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,8]]},"assertion":[{"value":"1 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"388"}}